Stealth’s lead investigational compound elamipretide targets the inner mitochondrialRelated to the mitochondria. membrane, binds to cardiolipin and has been shown to improve mitochondrial function. It is being studied in rare diseases linked to mitochondrial dysfunctionThis is when mitochondria do not work as well as they should due to another disease or condition. Many conditions can lead to secondary dysfunction. such as primary mitochondrial myopathy and Barth syndromeA rare, genetic disorder of lipid metabolism that primarily affects males.. Stealth will share lessons from the SPIMM 301 and TAZPOWER studies, explain how these results helped design the NuPOWER trial, describe how we think this product works and share information about their Expanded Access Program.
About the Speaker
Gene Kelly
Gene Kelly joined Stealth BioTherapeutics in 2014 and is currently the Executive Director of Medical Affairs. He has broad experience in pre-commercialization activities and has held leadership roles at both public and private biotechnology companies. Gene has worked closely with Mitochondrial Medicine Experts and Rare Disease Patient Advocacy Groups to gain insights that guide clinical development and disease awareness programs. He holds a bachelor’s degree in Pharmacy.
